This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
Browsing: Disease Area > Lung
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
An innovative new platform could transform the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells.
From clinical trial results to major drug approvals, here we present an overview of the latest industry news from the biggest players in oncology.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
Discover whether radiotherapy may have a promising role in synergistically enhancing the systemic response to immune checkpoint inhibition in this editorial from Future Oncology.
In this review piece, we take a look at the most read cancer news stories from over the past year; highlights include drug approvals, genetic discoveries and immunotherapy advancements.